A phase II study found that treatment with the antibody-drug conjugate enfortumab vedotin achieved responses in 44% of patients with locally advanced or metastatic urothelial cancer previously treated with platinum chemotherapy and" a checkpoint inhibitor. This is a noteworthy study because it addresses the new question of what to do after patients with metastatic urothelial cancer experience disease progression on second-line treatment with a checkpoint inhibitor.
展开▼
